123 related articles for article (PubMed ID: 12409075)
1. Arzoxifene in breast cancer.
Chan S
Eur J Cancer; 2002 Nov; 38 Suppl 6():S55-6. PubMed ID: 12409075
[No Abstract] [Full Text] [Related]
2. Arzoxifene: the development and clinical outcome of an ideal SERM.
Munster PN
Expert Opin Investig Drugs; 2006 Mar; 15(3):317-26. PubMed ID: 16503767
[TBL] [Abstract][Full Text] [Related]
3. Arzoxifene: a promising new selective estrogen receptor modulator for clinical chemoprevention of breast cancer.
Sporn MB
Clin Cancer Res; 2004 Aug; 10(16):5313-5. PubMed ID: 15328166
[No Abstract] [Full Text] [Related]
4. Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients.
Baselga J; Llombart-Cussac A; Bellet M; Guillem-Porta V; Enas N; Krejcy K; Carrasco E; Kayitalire L; Kuta M; Lluch A; Vodvarka P; Kerbrat P; Namer M; Petruzelka L
Ann Oncol; 2003 Sep; 14(9):1383-90. PubMed ID: 12954577
[TBL] [Abstract][Full Text] [Related]
5. Prevention of breast cancer by newer SERMs in the future.
Powles T
Recent Results Cancer Res; 2011; 188():141-5. PubMed ID: 21253796
[TBL] [Abstract][Full Text] [Related]
6. The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells.
Freddie CT; Larsen SS; Bartholomaeussen M; Lykkesfeldt AE
Mol Cell Endocrinol; 2004 Apr; 219(1-2):27-36. PubMed ID: 15149724
[TBL] [Abstract][Full Text] [Related]
7. Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women.
Cummings SR; McClung M; Reginster JY; Cox D; Mitlak B; Stock J; Amewou-Atisso M; Powles T; Miller P; Zanchetta J; Christiansen C
J Bone Miner Res; 2011 Feb; 26(2):397-404. PubMed ID: 20658564
[TBL] [Abstract][Full Text] [Related]
8. Arzoxifene as therapy for endometrial cancer.
Burke TW; Walker CL
Gynecol Oncol; 2003 Aug; 90(2 Pt 2):S40-6. PubMed ID: 12928005
[TBL] [Abstract][Full Text] [Related]
9. [Third generation selective estrogen receptor modulators: benefits beyond bone. II, endometrial action].
Calaf Alsina J; Coronado MartÃn PJ
Med Clin (Barc); 2013 Mar; 140(6):266-71. PubMed ID: 23276611
[TBL] [Abstract][Full Text] [Related]
10. Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268.
Suh N; Lamph WW; Glasebrook AL; Grese TA; Palkowitz AD; Williams CR; Risingsong R; Farris MR; Heyman RA; Sporn MB
Clin Cancer Res; 2002 Oct; 8(10):3270-5. PubMed ID: 12374698
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer chemoprevention: a review of selective estrogen receptor modulators.
Johansen AM
Clin J Oncol Nurs; 2005 Jun; 9(3):317-20. PubMed ID: 15973842
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene.
Powles TJ; Diem SJ; Fabian CJ; Neven P; Wickerham DL; Cox DA; Muram D; Agnusdei D; Dowsett SA; Amewou-Atisso M; Cummings SR
Breast Cancer Res Treat; 2012 Jul; 134(1):299-306. PubMed ID: 22484799
[TBL] [Abstract][Full Text] [Related]
13. Effect of the selective estrogen receptor modulator arzoxifene on repopulation of hormone-responsive breast cancer xenografts between courses of chemotherapy.
Wu L; Tannock IF
Clin Cancer Res; 2005 Nov; 11(22):8195-200. PubMed ID: 16299252
[TBL] [Abstract][Full Text] [Related]
14. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer.
Buzdar A; O'Shaughnessy JA; Booser DJ; Pippen JE; Jones SE; Munster PN; Peterson P; Melemed AS; Winer E; Hudis C
J Clin Oncol; 2003 Mar; 21(6):1007-14. PubMed ID: 12637464
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator.
Fabian CJ; Kimler BF; Anderson J; Tawfik OW; Mayo MS; Burak WE; O'Shaughnessy JA; Albain KS; Hyams DM; Budd GT; Ganz PA; Sauter ER; Beenken SW; Grizzle WE; Fruehauf JP; Arneson DW; Bacus JW; Lagios MD; Johnson KA; Browne D
Clin Cancer Res; 2004 Aug; 10(16):5403-17. PubMed ID: 15328178
[TBL] [Abstract][Full Text] [Related]
16. Preventive therapy for breast cancer: a consensus statement.
Cuzick J; DeCensi A; Arun B; Brown PH; Castiglione M; Dunn B; Forbes JF; Glaus A; Howell A; von Minckwitz G; Vogel V; Zwierzina H
Lancet Oncol; 2011 May; 12(5):496-503. PubMed ID: 21441069
[TBL] [Abstract][Full Text] [Related]
17. Upstaging tamoxifen? New classes of drugs emerging for breast cancer.
Twombly R
J Natl Cancer Inst; 2002 Apr; 94(7):474-5. PubMed ID: 11929942
[No Abstract] [Full Text] [Related]
18. The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer.
Liby K; Rendi M; Suh N; Royce DB; Risingsong R; Williams CR; Lamph W; Labrie F; Krajewski S; Xu X; Kim H; Brown P; Sporn MB
Clin Cancer Res; 2006 Oct; 12(19):5902-9. PubMed ID: 17020999
[TBL] [Abstract][Full Text] [Related]
19. The oestrogen receptor and its selective modulators in gynaecological oncology.
Seifert M; Galid A; Kubista E
Eur J Cancer; 2000 Sep; 36 Suppl 4():S66-7. PubMed ID: 11056325
[No Abstract] [Full Text] [Related]
20. Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass.
Goldstein SR; Bhattoa HP; Neven P; Cox DA; Dowsett SA; Alam J; Sipos A; Muram D
Menopause; 2012 Jan; 19(1):41-7. PubMed ID: 21993078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]